Boston Scientific Confirms Common Stock Trading Symbol BSX

TL;DR

**BSX filed an 8-K confirming its common stock trading symbol and par value.**

AI Summary

Boston Scientific Corporation filed an 8-K on January 8, 2024, to disclose that its Common Stock, with a $0.01 par value per share, is registered for trading under the symbol BSX. This filing, under Regulation FD Disclosure, confirms the company's compliance with SEC reporting requirements. This matters to investors because it reaffirms the public trading status of their shares and ensures transparency regarding the company's foundational stock information.

Why It Matters

This filing confirms the basic trading information for Boston Scientific's stock, providing clarity and ensuring regulatory compliance for investors.

Risk Assessment

Risk Level: low — This filing is purely informational, confirming existing stock details and poses no new financial or operational risks.

Analyst Insight

A smart investor would note this filing as a routine compliance update, confirming the stability of basic stock information, but it doesn't warrant immediate action.

Key Numbers

• $0.01 — par value per share (the stated par value for Boston Scientific's Common Stock)

Key Players & Entities

• BOSTON SCIENTIFIC CORPORATION (company) — the registrant filing the 8-K
• $0.01 (dollar_amount) — par value per share of Common Stock
• BSX (company) — trading symbol for Common Stock
• January 8, 2024 (date) — date of earliest event reported and filing date

Forward-Looking Statements

• Boston Scientific will continue to trade under the BSX ticker. (BOSTON SCIENTIFIC CORPORATION) — high confidence, target: N/A

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock

Filing Documents

• bsx-20240108.htm (8-K) — 38KB
• pressreleasedatedjanuary82.htm (EX-99.1) — 22KB
• investorpresentationdate.htm (EX-99.2) — 13KB
• pressreleasesadie.jpg (GRAPHIC) — 38KB
• investorpresentationdate001.jpg (GRAPHIC) — 57KB
• investorpresentationdate002.jpg (GRAPHIC) — 253KB
• investorpresentationdate003.jpg (GRAPHIC) — 136KB
• investorpresentationdate004.jpg (GRAPHIC) — 147KB
• investorpresentationdate005.jpg (GRAPHIC) — 124KB
• investorpresentationdate006.jpg (GRAPHIC) — 126KB
• investorpresentationdate007.jpg (GRAPHIC) — 31KB
• investorpresentationdate008.jpg (GRAPHIC) — 146KB
• 0000885725-24-000003.txt ( ) — 1709KB
• bsx-20240108.xsd (EX-101.SCH) — 3KB
• bsx-20240108_def.xml (EX-101.DEF) — 15KB
• bsx-20240108_lab.xml (EX-101.LAB) — 30KB
• bsx-20240108_pre.xml (EX-101.PRE) — 16KB
• bsx-20240108_htm.xml (XML) — 4KB

01 REGULATION FD

Item 7.01 REGULATION FD On January 8, 2024, Boston Scientific Corporation (the " Company ") issued a press release (the " Press Release ") announcing that the Company and Axonics, Inc. (" Axonics ") have executed a definitive agreement pursuant to which the Company agreed to acquire Axonics (the " Transaction ") on the terms and subject to the conditions set forth in the definitive agreement. Also, on January 8, 2024, the Company made available on its website an investor presentation (the " Investor Presentation ") regarding the Transaction. The acquisition is expected to close in the first half of 2024, subject to customary closing conditions. A copy of the Press Release and the Investor Presentation are attached to this report as Exhibit 99.1 and Exhibit 99.2, respectively and are incorporated herein by reference; provided, however, that information on or connected to the Company's website or the website of any third-party hyperlinked from or referenced in the Press Release or the Investor Presentation are expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, as well as Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Statement Regarding Forward-Looking Statements Certain statements that we may make from time to time, including statements contained in this Current Report on Form 8-K and information incorporated by reference herein, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Fo

01. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 8, 2024 99.2 Investor Presentation, dated January 8, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel, and Assistant Secretary

View Full Filing

View this 8-K filing on SEC EDGAR